Condition P12
Polycystic ovary syndrome
Women with polycystic ovary syndrome.
16 randomized trials; 13 fitted analyses across 10 outcomes.
All outcomes
Each outcome is analyzed per time window and estimand, with doses kept apart (each dose) and pooled (each medicine). Analyses with too few connected trials are shown as descriptive.
Ovulationprimary
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| weeks 12 to 52 (target week 26) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| weeks 12 to 52 (target week 26) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
Percent body weight change (short trials)primary
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| weeks 12 to 52 (target week 24) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| weeks 12 to 52 (target week 24) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
Serious adverse events
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 3 | 3 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately | 2 | 3 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 1 | 2 | Descriptive only |
Discontinuation due to adverse events
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Each dose separately (part 3) | 2 | 3 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled (part 2) | 2 | 3 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled (part 3) | 2 | 3 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 4) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled | 1 | 2 | Descriptive only |
Nausea
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 8 | 5 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately | 7 | 7 | Network meta-analysis |
| longest follow-up | Recorded harms | Doses of a drug pooled (part 2) | 2 | 3 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 2 | 3 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately (part 3) | 1 | 2 | Descriptive only |
Vomiting
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 5 | 5 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately | 3 | 3 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled (part 2) | 2 | 3 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 2 | 3 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 4) | 1 | 3 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 3) | 1 | 2 | Descriptive only |
Diarrhea
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 8 | 5 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately | 7 | 7 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 2 | 3 | Network meta-analysis |
| longest follow-up | Recorded harms | Doses of a drug pooled (part 2) | 2 | 3 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately (part 3) | 1 | 2 | Descriptive only |
Constipation
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 3 | 2 | Pairwise meta-analysis |
| longest follow-up | Recorded harms | Each dose separately | 3 | 3 | Network meta-analysis |
| longest follow-up | Recorded harms | Doses of a drug pooled (part 2) | 2 | 3 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 2 | 3 | Descriptive only |
Discontinuation due to gastrointestinal adverse events
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Each dose separately (part 2) | 2 | 3 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled (part 2) | 2 | 3 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled | 1 | 2 | Descriptive only |
Regular menstrual cycles
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| weeks 12 to 52 (target week 26) | Not stated by the trials | Doses of a drug pooled | 3 | 4 | Network meta-analysis |
| weeks 12 to 52 (target week 26) | Not stated by the trials | Each dose separately | 2 | 3 | Network meta-analysis |
| weeks 12 to 52 (target week 26) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |